Mesenchymal stem cells differentially mediate regulatory T cells and conventional effector T cells to protect fully allogeneic islet grafts in mice
- First Online:
- Cite this article as:
- Xu, D.M., Yu, X.F., Zhang, D. et al. Diabetologia (2012) 55: 1091. doi:10.1007/s00125-011-2433-9
- 561 Downloads
Limited information is available on the cellular interactions between regulatory T (Treg) cells and mesenchymal stem cells (MSCs). In particular, a direct effect of MSCs on the survival and proliferation of Treg cells has not been demonstrated.
We investigated the effects of MSCs on effector T (Teff) cells and Treg cells, and the molecular mechanisms involved in the distinct regulation of these two cell populations by MSCs in vivo and in vitro.
We show that MSCs are capable of selectively suppressing Teff cells and fostering the generation of Treg cells. Teff cells, but not Treg cells, fail to respond to IL-2 and undergo profound apoptosis in the presence of MSCs. The differential regulations of these two T cell subsets by MSCs are associated with their distinct expressions of CD25, with MSCs specifically reducing the expression of CD25 on Teff and sparing Treg cells intact. In vivo, the administration of MSCs significantly delays the rejection of allogeneic islet grafts in adaptive transferred recipients by favouring the induction of Treg cells. In this model, MSCs inhibit the proliferation and development of alloreactive Teff but potently enhance the induction of Treg cells.
We demonstrate that MSCs are capable of regulating Teff and Treg cells differentially in vitro. MSCs inhibit Teff cells by inducing apoptosis and impairing the proliferative response to IL-2 in Teff cells, but favour the survival and expansion of Treg cells. This result is further demonstrated in mice that have undergone allogeneic islet transplantation, in which MSCs suppress alloreactive Teff cells while favouring the induction of Treg cells, thus protecting the islet allografts from rejection.
KeywordsImmunosuppressionIslet transplantationMesenchymal stem cells
Bone marrow flushed cell
5,6-Carboxyfluorescein diacetate succinimidyl ester
Forkhead box P3
Mean fluorescent intensity
Mesenchymal stem cell
Effector T cells
Regulatory T cells
Mesenchymal stem cells (MSCs) are a rare subset of cells within the bone marrow cavity with proliferative capacity and an ability to differentiate into a variety of mesodermal tissues [1–3]. The suppressive capabilities of MSCs are exploited to control several subsets of immune cells as well as to reduce inflammatory cytokine production [4, 5]. MSCs have been shown to inhibit effector T (Teff) lymphocyte proliferation induced by alloantigens or mitogens [4, 6, 7]. Recently, we showed that MSCs exert potent immunosuppressive properties by reducing the surface expression of CD25, the alpha subunit of the IL-2 receptor, on Teff cells, thus blocking the IL-2 cytokine signalling pathway required for T lymphocyte activation, expansion and differentiation . By targetting the detrimental alloreactive T cell response, MSCs have been shown to exhibit therapeutic potential in controlling or preventing graft rejection in many experimental animal models of organ transplantation [9–11].
CD25+CD4+ regulatory T cells (Treg), which account for 5–10% of CD4 T cells, are an important cellular subset with immunosuppressive activity that have been demonstrated to suppress immune responses directed against allografts as well as against pathogen antigens in mice and humans [12, 13]. Rather than being subjected to MSC-mediated immunosuppression like their CD4+CD25− Teff counterparts, it has been reported that Treg cells can be induced by MSCs in vitro and in patients following autologous MSC therapy [14–16]. However, the precise mechanisms mediating such differential effects remain elusive. This is an important question that needs to be addressed in order to develop MSC-based immunotherapy that allows a selective targetting of alloreactive Teff cells while sparing Treg cells with regulatory activities.
Islet transplantation offers an attractive and effective approach to the treatment of patients with type 1 diabetes, and can lead to a normal metabolic control of glucose levels and an independence from exogenous insulin . Despite great success in terms of restoring normoglycaemia, the long-term efficacy of this approach after transplantation has been limited due to chronic graft rejection . Immunosuppressive regimens used in the Edmonton protocol and its derivatives [17, 19], such as tacrolimus, have been found to affect the calcineurin-dependent IL-2 production that is critical for Treg function and expansion in preventing graft rejection . Thus, an optimal approach would involve an improved islet transplantation protocol that would prevent graft rejection without the need for potentially dangerous long-term and non-specific immune suppression. Previous reports , including our own results , have shown that the infusion of MSCs results in a reversal of rejection episodes and a prolongation of islet function in islet-transplanted animal models, cementing the rationale for the therapeutic application of MSCs in allogeneic islet transplantation. The precise mechanisms involved in the beneficial effects of MSCs in allogeneic islet transplantation, however, require further investigation.
In this study, we demonstrate the differential regulation by MSCs of Teff and Treg cells with regard to their differences in expansion, survival and response to IL-2. Our results show that MSCs are capable of fostering the survival and expansion of Treg cells while inducing potent apoptosis and an impaired proliferative response to IL-2 in Teff cells. To explore the functionality of MSCs with regulatory activity in vivo, we used a mouse islet allograft transplantation model with BALB/c Rag−/−γ−/− mice, deficient in T, B and natural killer cells, as recipients. Using these, we analysed the rejection response against MHC fully mismatched C57BL/6 islet allografts and assessed the impact of MSCs with regulatory activity on the modulation of this response in vivo.
C57BL/6 (B6, H2b), BALB/c (H2d), and BALB/c Rag−/−γ−/− mice were originally purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The mice were bred and housed under specific pathogen-free conditions at the Tongji Medical School Facilities for Animal Care and Housing, and were between 6 and 8 weeks of age at the time of the first procedure. All animal studies were carried out according to the guidelines of the Chinese Council on Animal Care and were approved by the Tongji Medical College Committees on Animal Experimentation.
Bone marrow cells were collected from the femurs and tibias of BALB/c mice by a standard flushing method, and cultured according to the protocol previously described . The identification of all primary MSCs was confirmed by morphology, phenotypic analysis and their capability to differentiate into adipocytes and osteoblasts under appropriate culture conditions, as previously described . All experiments were set up within passage 10 of the MSC cultures.
Selection of CD4+CD25− T cells
CD4+CD25− Teff and CD4+CD25+ Treg cells were purified from the spleen of BALB/c mice using CD25 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany). Each preparation used in this study was greater than 95% pure by FACS analysis.
Standard 3-day cultures were set up in 96-well round-bottomed plates using 1 × 105 Teff or Treg cells stimulated by CD3/CD28 Dynabeads (Invitrogen, Carlsbad, CA, USA) in a 1:1 ratio with the number of T cells in the presence of 2 × 104 MSCs. Thymidine was added during the last 18 h of culture before measuring the incorporation of [3H]thymidine (3H-TdR) using a liquid scintillation counter.
Single-cell suspensions were generated from spleen and lymph nodes, and red cell lysis was performed by brief exposure to deionised water. Aliquots were then divided for various panels of analysis. Treg cells were identified by co-expression of CD4 and CD25, and intracellular detection of forkhead box P3 (FOXP3). For cytokine analysis, cells were re-stimulated for 5 h with PMA (Sigma-Aldrich, St Louis, MO, USA) before being stained for intracellular IFN-γ, IL-10, IL-4 and TGF-β (BD Biosciences, San Diego, CA, USA).
Induction of diabetes
BALB/c Rag−/−γ−/− mice were rendered diabetic by a single intravenous injection of 200 mg/kg streptozotocin (STZ; Sigma-Aldrich). The dose of STZ was titrated to give a level of about 20 mmol/l blood glucose at the day of islet transplantation.
Islets were isolated from mouse pancreata (C57BL/6) by a discontinuous Ficoll gradient centrifugation as previously described , and were counted under a microscope after dithizone staining.
Adoptive transfer of cells and islet transplantation
A total of 500 IE C57BL/6 islets were transplantation into BALB/c Rag−/−γ−/− mice. Islets were aggregated in a clot of recipient (BALB/c) strain blood, and inserted into a subcapsular pocket of the left kidney. The grafts were allowed to normalise for 2 days before the adoptive transfer of allogeneic splenocytes. BALB/c Rag−/−γ−/− mice were reconstituted intraperitoneally with 1 × 106 splenocytes from naive BALB/c mice, or with 3 × 106 BALB/c MSCs or bone marrow flushed cells (BMFCs). Blood glucose levels were determined using a blood glucose meter (Accu-Chek Advantage Meter; Roche Diagnostics, Basel, Switzerland). Rejection was defined as a blood glucose level of more than 14.5 mmol/l for at least two consecutive days. In same experiments, graft function was determined by removing the kidney containing the transplanted islets.
To visualise the functional islets transplanted beneath the kidney capsule, kidneys were frozen in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA), and 10 μm sections were stained for insulin according to the protocols previously described . Nuclear counterstaining was performed using Hoechst dye, and sections were viewed with a Leica epifluorescence microscope (Leica Microsystems, Wetzlar, Germany).
Data are expressed as mean ± SE. Kaplan–Meier analysis was used for survival analysis with significance set at p < 0.05. The Student’s t test was used for two-tailed comparison.
MSCs suppress the proliferation of Teff but not Treg cells
MSCs obtained from BALB/c bone marrow cells are spindle-shaped, with a typical MSC phenotype—positive for CD44, CD73, CD105, and negative for CD11b—distinct from that of fibroblasts (data not shown). Under the appropriate culture conditions, the MSCs can be differentiated into adipogenic and osteogenic lineages, as verified by oil red O and Alizarin red staining (for adipogenic and osteogenic induction) .
To compare the regulatory effects of MSCs on the Teff and Treg populations, CD4+CD25− Teff and CD4+CD25+ naive Treg cells were isolated from single-cell suspensions of splenocytes, and were stimulated with anti-CD3/CD28 beads alone or in the presence of MSCs. Absolute cell numbers were quantified by flow cytometry after adding Calibrite beads (BD Biosciences) to the cultures. As shown in Fig. 1c, the presence of MSCs resulted in a significant reduction of the Teff population. Interestingly, in a converse regulatory fashion, MSCs induced the expansion of Treg cells, as demonstrated by a fourfold increase in the number of Treg cells co-cultured with MSCs compared with Treg cells cultured alone (5.44 ± 1.80 × 105 vs 1.34 ± 0.29 × 105, p < 0.01; Fig. 1d). The expanded cell populations induced by MSCs were defined as dominantly cells of the CD4+CD25+FOXP3+ Treg compartment (p < 0.01; Fig. 1e).
MSCs differentially regulate the survival and IL-2 response of Teff and Treg cells
We then considered whether the differential response to IL-2 of the Teff and Treg cells would remain after the MSCs had been removed. Treg or Teff cells co-cultured with MSCs in the primary cultures were re-isolated by positive selection and then incubated with exogenous IL-2 at different concentrations for another 72 h. As shown in Fig. 2b, Teff cells stimulated with anti-CD3/CD28 in the primary cultures with MSCs responded poorly to exogenous IL-2. Intriguingly, Treg cells co-cultured initially with MSCs proliferated vigorously in response to IL-2 in secondary cultures.
To determine whether the different responses to IL-2 of the Treg and Teff cells were related to the alteration in cell survival, we analysed the apoptosis of these two T cell subsets when co-cultured with MSCs. As shown in Fig. 2c, the presence of MSCs led to substantial apoptosis of the Teff cells: 81.8% of Teff cells co-cultured with MSCs were apoptotic, in clear contrast to a background level of apoptosis in Teff cells alone. Intriguingly, the addition of MSCs led to no statistical difference in Treg apoptosis (NS, p > 0.05), and Treg cells did not undergo apoptosis as Teff cells did in response to MSC treatment (10.8 ± 1.4% vs 81.8 ± 6.9%, p < 0.01; Fig. 2c). Taken together, these results demonstrate that MSCs mediated a selective inhibition of Teff cells by inducing apoptosis and preventing their proliferation in response to IL-2, but failed to affect the survival and proliferation of the Treg cells.
Teff, but not Treg, cells lose surface expression of CD25 in the presence of MSCs
We and other groups have previously demonstrated that the MSC-mediated suppression of T cell proliferation is related to a significant reduction in CD25 expression on the activated T cells [8, 23, 24]. CD25, known as the alpha subunit of the IL-2 receptor, is constitutively expressed on the surface of Treg cells and plays an important role in the survival and expansion of these cell populations [25–27]. We therefore sought to determine whether the different response to IL-2 of Teff and Treg cells induced by MSCs was related to the expression of CD25 on these two T cell subsets.
We then examined the dynamic expression of CD25 on Teff and Treg cells when co-cultured with MSCs for 24, 48 and 72 h. Our results showed that, although the presence of MSCs had no effect on Treg cells, the addition of MSCs resulted in a significant reduction in CD25 expression by Teff after 2 days (p < 0.01, Fig. 3e, f), suggesting the differential regulation by MSCs of the surface expression of CD25 in Teff and Treg cells. Additional evidence for this differential regulation is that the presence of MSCs resulted in a statistically significant reduction of CD25 expression only on CD4+CD25+FOXP3− Teff cells, whereas there was no effect on CD4+CD25+FOXP3+ Treg cells when the total population of T cells containing both T cell compartments was stimulated with anti-CD3/CD28 beads in culture (Fig. 3g). Thus, these results indicate that MSCs specifically modulated the expression of CD25 on Teff and spared Treg cells intact.
MSCs protect islet allografts from rejection
Islet grafts were allowed to normalise for 2 days before the adoptive transfer of allogeneic splenocytes. As shown in Fig. 4a,b, acute rejection of the islet allografts was observed in all recipients, with a median graft survival time (MST) of 16 days after the adoptive transfer of an effector population (control, n = 5). However, when the MSCs were co-transfered along with whole splenocytes, islet allograft survival was dramatically prolonged, with a MST of postoperative day (POD) 38 (n = 5, +MSC vs 16 POD in a control group, p < 0.01; Fig. 4b). This effect was due solely to the survival of the transplanted islets and not to endogenous islet regeneration, as demonstrated by the fact that removal of the transplanted islets by nephrectomy in normoglycaemic recipients at day 38 resulted in an abrupt return to hyperglycaemia (Fig. 4a, arrow). Glucose homeostasis in BMFC co-transfer animals (+BMFC) was comparable to that in the untreated control group (n = 4, +BMFC vs control, p > 0.05; Fig. 4b), and the animals became profoundly diabetic within 15–22 days (MST = 16.5 days) as a result of unmodified allograft rejection. MSC-protected grafts, which showed as insulin-positive mass, were readily detected in the kidneys (+MSC; Fig. 4c) but were completely absent from mice administered BMFCs and from the control group.
These results demonstrate the beneficial effects of MSCs on graft survival in the mouse islet allograft model, although MSCs appeared to be unable to alter the tempo of rejection in the more stringently immunocompetent recipients: both MSC-treated and control mice promptly rejected grafts post-transplantation (C57BL/6 to BALB/c, data not shown). Furthermore, the protective activities of MSCs on the survival of islet grafts correlated with a substantial reduction in T cell infiltration into the islet grafts (3.2% in the +MSC vs 11.4% in the control and 14.7% in +BMFC groups; Fig. 4d) and an induction of CD4+FOXP3+ Treg cells (17.6% in the +MSC group vs 9.2% in controls; Fig. 4e).
MSCs suppress the proliferation of Teff cells in vivo
MSCs affect Teff cell differentiation in vivo and in vitro
We further investigated the development of Teff cells in islet-transplanted recipients after the administration of MSCs or BMFCs, comparing these with the controls. At the time of rejection, or at the endpoint of the observation period, spleens from BALB/c Rag−/−γ−/− mice adoptively transferred with splenocytes were harvested and analysed by flow cytometry. In parallel with the observations in vitro, MSC co-transfer dramatically prevented the production of IFN-γ by CD4+ T cells (+MSCs vs control, p < 0.01; Fig. 6b); meanwhile, treatment with BMFCs led to little change in IFN-γ production (+BMFCs vs control, NS [p > 0.05]; Fig. 6b). Conversely, IL-10 production was significantly elevated in the group given MSCs compared with the BMFC-treated and control groups (p < 0.01; Fig. 6c). MSC treatment, however, led to no effect on IL-4 and TGF-β production, and the frequency of CD4+IL-4+ and TGF-β+ cells remained unchanged in comparison with the control group (+MSCs vs control; N.S p > 0.05; Fig. 6d, e). Hence, our data demonstrate that MSCs were capable of modulating the allogeneic rejection response against islet allografts both in vitro and in an in vivo model of allogeneic islet transplantation.
MSCs suppress alloreactivity by inducing Treg cells in vivo
Next, we tested the immunological tolerance induced in the MSC-treated recipients in standard mixed lymphocyte reactions (MLR). Splenocytes from mice that had been treated with MSCs were harvested at the endpoint of observation, and those from mice treated with MSCs and mice in the control group were harvested when the islet allograft was rejected. Irradiated splenocytes from naive BALB/c, C57BL/6 and CBA mice served as antigen-presenting cells. The MLR assay revealed that splenocytes from recipients administered MSCs displayed a low level of cell proliferation in response to donor antigen-presenting cells compared with cells from the BMFC-treated group (p < 0.05; Fig. 7b), whereas the response to third-party CBA stimulation remained normal.
To specifically modulate aberrant immune responses such as autoimmune disorders, allograft rejection or graft-vs-host disease by immunosuppressive therapy, while sparing Treg activity, it is crucial to obtain a more detailed insight into the biological differences between Teff and Treg cells. It is well recognised that MSCs can inhibit T cell responses induced by mitogens or alloantigens [4, 28]. Recently, it has been shown that regulatory lymphocytes are generated in co-cultures of peripheral blood mononuclear cells with MSCs, which may potentiate the MSC-mediated immunosuppressive effect [14, 16].
Despite the far-reaching applications of MSCs in clinical situations, questions remain with regard to the mechanisms underlying the actions of MSC on Teff and Treg cells. In this paper, we characterised the impact of MSCs on the expansion and survival of CD4+CD25+FOXP3+ Treg cells, as well as their proliferative response to IL-2, and found important differences compared with their CD4+CD25− Teff counterparts. Teff cells co-cultured with MSCs failed to respond to IL-2 stimulation and were more prone to apoptosis, in contrast to Treg cells, which had a normal proliferative response to IL-2. The differential regulation of Teff and Treg cells by MSCs may provide novel insights into the development of successful immunotherapy in order to obtain a sufficient number of Treg cells for clinical purposes, while reducing the risk of eliciting an unwanted alloreactive response in vivo.
The steadily growing interest in MSC-mediated immunosuppression has involved its potential in the activation, expansion and induction of Treg cells from conventional CD4+ Teff cells both in vivo and in vitro [29–31]. We previously demonstrated that matrix metalloproteinases -2 and -9 secreted by MSCs play an important role in MSC-mediated suppressive activity by reducing the surface expression of CD25 on activated Teff cells . Regulatory CD4+ T cells also constitutively express CD25. As an important Treg marker, CD25 has been reported to be critical in the maintenance and expansion of Treg populations [26, 32]. It is also required for sustained expression of FOXP3 and enhances the suppressive capacity of Treg cells . We therefore aimed to study the impact of MSCs on CD25 expression of Treg cells and its functional importance on cell survival and proliferation.
Intriguingly, we found that MSCs differentially regulated CD25 expression on Treg and Teff cells. Despite being co-cultured with MSCs, CD25 expression on Treg cells remained intact, in clear contrast to the reduced CD25 expression on Teff cells. The differential regulation by MSCs of CD25 expression on different T cell compartments was functionally correlated with their survival and proliferative responses to IL-2. Taking all our results together, we have for the first time demonstrated that MSCs are capable of selectively fostering the survival and expansion of Treg cells, while inhibiting Teff cells by inducing apoptosis and an impaired response to IL-2.
Emerging evidence has suggested that MSCs may offer therapeutic opportunities in islet transplantation by blunting the effector arm of the alloreactive response [3, 34]. Our findings that MSCs preferentially inhibit the expansion of Teff cells while sparing Treg activity prompted us to analyse the therapeutic potential of MSCs in an islet-transplanted mouse model. Recently, the therapeutic effects of MSCs in islet transplantation have been described in a non-primate animal model in which MSC treatment significantly enhanced islet engraftment and resulted in a reversal of rejection episodes .
In alignment with this study, we showed that co-administration of MSCs with allogeneic splenocytes led to a profound inhibition of the alloreactive response, a dramatic reduction in IFN-γ and an augmented production of IL-10, and as a result favoured the induction of peripheral tolerance. Our results that treatment with MSCs resulted in an enhanced production of IL-10, with no effect on the level of TGF-β, suggest that IL-10 rather than TGF-β could be involved in the functionality of these induced Treg cells. Moreover, our results provide evidence that the immunosuppressive activity of MSCs occurs in a donor-specific manner since the alloresponse against a third unrelated party was largely intact. Nevertheless, it is unlikely that MSCs could be used as a stand-alone therapy in islet transplantation as the administration of MSCs apparently has no substantial therapeutic effect in immunocompetent murine recipients (data not shown). Further studies are warranted in order to optimise MSC-based therapy, especially its dosage and route, as well as possible combinations with accepted immunosuppressants.
Taken together, our results suggest that MSCs may hold the potential not only for the suppression of conventional Teff cells, but also in the development of applications that could benefit transplantation through inducing the proliferation of Treg cells. These findings cement the rationale for their implication in clinical islet transplantation.
The authors are grateful to the staff at the Tongji Medical School Facilities for Animal Care and Housing for animal welfare. We thank DLV Bauer (Wellcome Trust Centre for Human Genetics, University of Oxford) for proofreading the manuscript.
This work was supported in part by grants from the Research Foundation for Talented Scholars of the Huazhong University of Science and Technology and the National Natural Science Foundation of China (81101572).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
DMX and YCD contributed to the conception and design of the research, conducting the experiments, data analysis and interpretation and manuscript writing, and gave final approval of manuscript. XFY, DZ, MXZ, JFZ and PHT contributed to analysis and interpretation of data, revised the draft critically for important intellectual content and gave approval of the final version to be published.